GSK to Acquire Nuvalent for $10.6 Billion to Boost Oncology Pipeline
L'essentiel
GSK acquires Nuvalent for $10.6B to bolster oncology pipeline with late-stage lung cancer treatments, aiming to offset future revenue drop from losing HIV medicine exclusivity.
Résumé généré par IA
Pourquoi c'est important
GSK seeks to strengthen its oncology portfolio amid upcoming revenue challenges.
Britain's second-largest drugmaker GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its oncology pipeline, in what would be its largest acquisition in more than a decade. The all-cash deal values Nuvalent at about $124 per share, according to a GSK filing on Tuesday, representing a 40% premium to its last closing price. Nuvalent shares were last seen trading 39% higher in U.S. premarket trading. GSK shares fell 2.6% in London. [...]
À surveiller
Perspective IA — des possibilités, pas des certitudes
Nuvalent's lead assets to receive FDA approval by end of 2026.
Probable · En quelques jours
GSK's revenue to show significant growth from 2027 onwards.
Très probable · En quelques mois
Questions ouvertes
- Long-term market performance of Nuvalent's assets post-acquisition
